Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 266-803-5 | CAS number: 67634-00-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- dose selection is not appropriate
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted on 3rd October, 2008
- Deviations:
- yes
- Remarks:
- no limit test were completed
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species Rattus norvegicus (rat)
Strain Wistar
Age 8 to 12 weeks
Weight Range (g)
(Start of experiment) 127.14 to 195.27
Sex Male & Female (nulliparous & non-pregnant)
Source Sainath agencies, Hyderabad, India.
This supplier is approved by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India for breeding laboratory animals.
Number of animals 30 M & 30 F
No of groups 6 - Route of administration:
- oral: gavage
- Details on route of administration:
- Test item was formulated in sesame oil for dose preparation and administered by oral gavage.
- Vehicle:
- other: sesame oil
- Duration of treatment / exposure:
- The test item dose was administered to rats daily for a period of 28-days as given below:
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- The test item dose was administered to rats daily for a period of 28-days as given below:
Group No. No & Sex of animals Dose Route of Administration Dose Volume
G1 5 M + 5 F Control group: Sesame oil Oral 1 mL/100g b. w.
G2 5 M + 5 F Low dose: 25 mg/kg b.w. Oral 1 mL/100g b. w.
G3 5 M + 5 F Mid dose: 50 mg/kg b.w. Oral 1 mL/100g b. w.
G4 5 M + 5 F High dose: 100 mg/kg b.w.Oral 1 mL/100g b. w.
G5 5 M + 5 F Control group: Reversal Oral 1 mL/100g b. w.
G6 5 M + 5 F High dose: Reversal Oral 1 mL/100g b. w.
M, Male; F, Female
Weekly body weight of animals were taken; and appropriate dose volume was administered for the next week. - Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- Mortality & Morbidity
All the animals were observed for mortality and morbidity throughout the study period.
Body Weight
Body weight of each animal was recorded immediately before dosing, weekly after the first dose and at the end of the study.
Feed and Water Consumption
Feed and water consumption was recorded daily throughout the experiment.
Clinical Observation
Clinical observations were made at least once in a day, throughout the study period, preferably at the same time of each day and recorded. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- None of the animals from any group showed any clinical signs of toxicity during the treatment.
- Mortality:
- no mortality observed
- Description (incidence):
- No morbidity & mortality was observed in any of the animals from the control and treatment group.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- All rats of the treated groups did not show statistically significant changes when compared to the vehicle control groups. Similar findings were observed in reversal groups.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Feed and water consumption was recorded cage wise daily and reported on a weekly basis. There were no statistically significant changes observed in any of the groups.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- Feed and water consumption was recorded cage wise daily and reported on a weekly basis. There were no statistically significant changes observed in any of the groups.
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Hematology and Clinical Biochemistry
No statistical significant changes were observed in the treated groups when compared with the vehicle control groups. - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Hematology and Clinical Biochemistry
No statistical significant changes were observed in the treated groups when compared with the vehicle control groups. - Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Organ Weights
No statistical significant changes in relative as well as absolute organ weights in any of the groups. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Gross Pathology
Most tissues were macroscopically unremarkable and the findings seen were generally consistent with the usual pattern of findings in animals of this strain and age. There were no findings of an unusual nature. There were no macroscopic findings suggestive of effects of the test item. - Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Histopathology
Microscopic findings were generally infrequent, of a minor nature and consistent with the usual pattern of findings in animals of this strain and age. There were no microscopic findings in treated animals due to effects of the test item. - Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- Histopathology
Microscopic findings were generally infrequent, of a minor nature and consistent with the usual pattern of findings in animals of this strain and age. There were no microscopic findings in treated animals due to effects of the test item. - Other effects:
- not specified
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- > 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: neoplastic
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- water consumption and compound intake
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Conclusions:
- Based upon the results obtained in this study and in line with OECD 407: 2008 it is concluded that, the given test item, Allyl Amyl Glycolate, supplied by MORAYA GLOBAL LIMITED, did not produce any systemic toxicity following 28 days oral repeated dosing. The No-Observed Adverse Effect Level (NOAEL) value is greater than 100 mg/kg of bodyweight.
- Executive summary:
Based upon the results obtained in this study and in line with OECD 407: 2008 it is concluded that, the given test item,AllylAmyl Glycolate, supplied byMORAYA GLOBAL LIMITED, did not produce any systemic toxicity following 28 days oral repeated dosing.The No-Observed Adverse Effect Level (NOAEL) value is greater than 100 mg/kg of bodyweight.
This study was performed to evaluate the toxicity profile, arising from a repeated dose of Allyl Amyl Glycolate, when administered by orally to rats for a period of 28 days.
Test item was freshly formulated in sesame oil for each day of dosing.
Sixty rats were randomly distributed into six groups (five males and five females (nulliparous and non-pregnant) per group; G1 - Control group: Sesame oil; G2 - Low dose: 25 mg/kg b.w.; G3 - Mid dose: 50 mg/kg b.w.; G4 - High dose: 100 mg/kg b.w.; G5 - Control group: Reversal; G6 - High dose: Reversal. Test item formulation was administered by oral gavage for 28 days. After 28 days, animals in group G5 and G6 were maintained for further 14 days without any test item treatment, for post treatment observation to find the reversibility of any observed effects and also to find out any delayed effects of the test item.
No mortality/morbidity or any clinical signs of toxicity was observed during the treatment period. Treated and control group of rats did not show statistically significant changes in body weight at different weeks. Feed and water consumption data did not show any statistically significant changes in any of the groups.
Haematology parameters (hematocrit, clotting time, hemoglobin concentration, red blood cell count, white blood cell count, WBC differential count and platelet count); biochemistry parameters (sodium, potassium, glucose, total cholesterol, urea nitrogen, creatinine, total protein, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase data did not show statistically significant changes in various parameters in different groups. No test item related gross pathological changes were recorded. There were no statistically significant changes in organ weights. There were no macroscopic or microscopic findings due to effects of the test item.
Based upon the results obtained in this study and in line with OECD 407: 2008 it is concluded that, the given test item,AllylAmyl Glycolate, supplied byMORAYA GLOBAL LIMITED, did not produce any systemic toxicity following 28 days oral repeated dosing.The No-Observed Adverse Effect Level (NOAEL) value is greater than 100 mg/kg of bodyweight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Klimisch 1 ( GLP)
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.